Although ACE inhibitors and AT1 receptor blockers provide extensive beneficial effects on hypertension and other cardiovascular diseases, there is still considerable interest in developing drugs that target the unique substrate of the renin–angiotensin system, with particular interest in developing ASOs since this therapeutic mode can be applied less frequently, while providing long lasting and highly specific control of blood pressure. This evidence concerns the gene REN and hypertensive disorder.